RxDoctor Payments Data

Jeffrey Polito, MD

Internal Medicine · Santa Barbara, CANPI 1679525034

Payments from drug & device makers

$1,759in general payments, 2019–2025

Across 163 payments — averaging $10.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$666
  • Merck$172
  • Astellas Pharma US Inc$152
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Amgen$112
  • Pfizer$89
  • plus $454 from 13 others

What the payments were for

  • Food & beverage$1,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,759 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$398,005
Medicare patients
1,041
Services billed
3,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate14$195,227
WakixPitolisant Hcl12$182,894
EliquisApixaban81$88,712
OzempicSemaglutide61$64,708
JardianceEmpagliflozin47$59,233
JanuviaSitagliptin Phosphate59$58,052
MounjaroTirzepatide41$50,620
MyrbetriqMirabegron42$28,624
Xigduo XrDapaglifloz Propaned/Metformin11$14,313
XareltoRivaroxaban12$13,633
Repatha SureclickEvolocumab15$12,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,972
Breo ElliptaFluticasone/Vilanterol13$11,444
TradjentaLinagliptin12$6,299
Clomipramine Hcl24$5,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$88,71281 claims
Boehringer IngelheimJardiance, Tradjenta$63$65,53359 claims
Novo NordiskOzempic$60$64,70861 claims
MerckJanuvia$172$58,05259 claims
Lilly USA, LLCMounjaro$22$50,62041 claims
Astellas Pharma US IncMyrbetriq$152$28,62442 claims
Johnson & JohnsonXarelto$15$13,63312 claims
AbbVieSynthroid$666$2,54546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →